The stake is worth 100 million euros ($118 million U.S.), Sartorius said. It plans to purchase CellGenix's remaining shares at the beginning of 2023 and 2026.

CellGenix is based in Freiburg, Germany, but also has a sales office in Boston. It produces and markets cell culture components like growth factors, cytokines, and media for cell and gene therapy purposes and in 2020 generated sales of more than 20 million euros ($23.6 million).

Sartorius plans to expand the company's Freiburg site for manufacturing purposes, it said.

Sartorius expands biopharma manufacturing in Slovenia
Sartorius plans to expand production facilities for purification products for vaccines and therapies at its facility in Ajdovscina, Slovenia.

Sartorius contributes to Penn State cell culture facility
Sartorius Stedim Biotech has donated $1.5 million to Pennsylvania State University (Penn State) for the creation of the Sartorius Cell Culture Facility,...

RoosterBio, Sartorius partner on cell and gene therapy manufacturing
RoosterBio and Sartorius have signed a strategic collaboration to advance the scale-up of human mesenchymal stem/stromal cell manufacturing for regenerative...

Sartorius to acquire Novasep's chromatography division
Sartorius has entered into an agreement through its subgroup Sartorius Stedim Biotech to acquire the chromatography process equipment division of Novasep.

Sartorius acquires WaterSep BioSeparations
Sartorius Stedim Biotech has acquired WaterSep BioSeparations for approximately $27 million plus an earn-out based on sales revenues through 2023...